NEW YORK, May 25, 2012 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at AEterna Zentaris Inc. ("AEterna" or the "Company") (NasdaqGM: AEZS).
The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose in a timely manner that AEterna's drug perifosine was not effective in treating colorectal cancer.
On April 2, 2012, AEterna announced that the Phase 3 "X-PECT" (Xeloda® and Perifosine Evaluation in Colorectal cancer Treatment) clinical trial evaluating perifosine and capecitabine (Xeloda®) in patients with refractory advanced colorectal cancer did not meet the primary endpoint of improving overall survival versus capecitabine and placebo. As a result of this news, the Company's stock plummeted $1.41 per share to close at $0.73 per share on April 2, 2012, a one-day decline of approximately 66% on high volume.
Request more information now by clicking here: www.faruqilaw.com/AEZS
If you purchased AEterna securities and would like to discuss your legal rights, visit www.faruqilaw.com/AEZS. You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org or email@example.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding AEterna's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential matter.
FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
Francis McConville, Esq.
Telephone: (877) 247-4292 or (212) 983-9330
SOURCE Faruqi & Faruqi, LLP